Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer

Janelle M. Fauci, Jenny M. Whitworth, Kellie E. Schneider, Akila Subramaniam, Bin Zhang, Peter J. Frederick, Larry Kilgore, J. Michael Straughn

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: Relative dose intensity (RDI) is the ratio of delivered dose intensity of chemotherapy to standard dose intensity. In this study, we sought to determine the prognostic significance of RDI in patients with epithelial ovarian cancer (EOC). Methods: A retrospective analysis of chemotherapy naïve patients treated between 2001 and 2008 with intravenous taxane and platinum was performed. RDI was calculated as the delivered dose intensity (total dose delivered/total time of therapy) divided by standard dose intensity calculated for each regimen and compared to progression-free survival (PFS). Multivariate recursive partitioning survival analysis was utilized. Results: 138 EOC patients completed initial taxane/platinum-based chemotherapy following surgical cytoreduction. The most common reasons for dose delays and reductions were thrombocytopenia (38%) and neutropenia (31%). 24% of treatment delays were due to social reasons such as transportation constraints or scheduling conflicts. The average RDI was 90% (range, 24-126%). The mean PFS was 31 months (range, 3-117). Patients that achieved an RDI between 70% and 110% had a mean PFS of 32 months compared to 20 months in patients with an RDI of < 70% or > 110% (p = 0.046). 14 patients (10%) had a RDI of < 70%. Conclusions: RDI is a significant predictor of survival in patients with EOC. Effort should be made to achieve an RDI of at least 70%. Dose reductions and treatment delays could be minimized by utilizing prophylactic colony stimulating factors and educating patients about the importance of adhering to their treatment schedule.

Original languageEnglish (US)
Pages (from-to)532-535
Number of pages4
JournalGynecologic Oncology
Volume122
Issue number3
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Drug Therapy
Disease-Free Survival
Therapeutics
Platinum
Colony-Stimulating Factors
Ovarian epithelial cancer
Survival Analysis
Neutropenia
Thrombocytopenia
Appointments and Schedules
Survival
taxane

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Fauci, J. M., Whitworth, J. M., Schneider, K. E., Subramaniam, A., Zhang, B., Frederick, P. J., ... Straughn, J. M. (2011). Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecologic Oncology, 122(3), 532-535. https://doi.org/10.1016/j.ygyno.2011.05.023

Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. / Fauci, Janelle M.; Whitworth, Jenny M.; Schneider, Kellie E.; Subramaniam, Akila; Zhang, Bin; Frederick, Peter J.; Kilgore, Larry; Straughn, J. Michael.

In: Gynecologic Oncology, Vol. 122, No. 3, 01.09.2011, p. 532-535.

Research output: Contribution to journalArticle

Fauci, JM, Whitworth, JM, Schneider, KE, Subramaniam, A, Zhang, B, Frederick, PJ, Kilgore, L & Straughn, JM 2011, 'Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer', Gynecologic Oncology, vol. 122, no. 3, pp. 532-535. https://doi.org/10.1016/j.ygyno.2011.05.023
Fauci, Janelle M. ; Whitworth, Jenny M. ; Schneider, Kellie E. ; Subramaniam, Akila ; Zhang, Bin ; Frederick, Peter J. ; Kilgore, Larry ; Straughn, J. Michael. / Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. In: Gynecologic Oncology. 2011 ; Vol. 122, No. 3. pp. 532-535.
@article{401d99be47814acf9ed1df425361872f,
title = "Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer",
abstract = "Objective: Relative dose intensity (RDI) is the ratio of delivered dose intensity of chemotherapy to standard dose intensity. In this study, we sought to determine the prognostic significance of RDI in patients with epithelial ovarian cancer (EOC). Methods: A retrospective analysis of chemotherapy na{\"i}ve patients treated between 2001 and 2008 with intravenous taxane and platinum was performed. RDI was calculated as the delivered dose intensity (total dose delivered/total time of therapy) divided by standard dose intensity calculated for each regimen and compared to progression-free survival (PFS). Multivariate recursive partitioning survival analysis was utilized. Results: 138 EOC patients completed initial taxane/platinum-based chemotherapy following surgical cytoreduction. The most common reasons for dose delays and reductions were thrombocytopenia (38{\%}) and neutropenia (31{\%}). 24{\%} of treatment delays were due to social reasons such as transportation constraints or scheduling conflicts. The average RDI was 90{\%} (range, 24-126{\%}). The mean PFS was 31 months (range, 3-117). Patients that achieved an RDI between 70{\%} and 110{\%} had a mean PFS of 32 months compared to 20 months in patients with an RDI of < 70{\%} or > 110{\%} (p = 0.046). 14 patients (10{\%}) had a RDI of < 70{\%}. Conclusions: RDI is a significant predictor of survival in patients with EOC. Effort should be made to achieve an RDI of at least 70{\%}. Dose reductions and treatment delays could be minimized by utilizing prophylactic colony stimulating factors and educating patients about the importance of adhering to their treatment schedule.",
author = "Fauci, {Janelle M.} and Whitworth, {Jenny M.} and Schneider, {Kellie E.} and Akila Subramaniam and Bin Zhang and Frederick, {Peter J.} and Larry Kilgore and Straughn, {J. Michael}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ygyno.2011.05.023",
language = "English (US)",
volume = "122",
pages = "532--535",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer

AU - Fauci, Janelle M.

AU - Whitworth, Jenny M.

AU - Schneider, Kellie E.

AU - Subramaniam, Akila

AU - Zhang, Bin

AU - Frederick, Peter J.

AU - Kilgore, Larry

AU - Straughn, J. Michael

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Objective: Relative dose intensity (RDI) is the ratio of delivered dose intensity of chemotherapy to standard dose intensity. In this study, we sought to determine the prognostic significance of RDI in patients with epithelial ovarian cancer (EOC). Methods: A retrospective analysis of chemotherapy naïve patients treated between 2001 and 2008 with intravenous taxane and platinum was performed. RDI was calculated as the delivered dose intensity (total dose delivered/total time of therapy) divided by standard dose intensity calculated for each regimen and compared to progression-free survival (PFS). Multivariate recursive partitioning survival analysis was utilized. Results: 138 EOC patients completed initial taxane/platinum-based chemotherapy following surgical cytoreduction. The most common reasons for dose delays and reductions were thrombocytopenia (38%) and neutropenia (31%). 24% of treatment delays were due to social reasons such as transportation constraints or scheduling conflicts. The average RDI was 90% (range, 24-126%). The mean PFS was 31 months (range, 3-117). Patients that achieved an RDI between 70% and 110% had a mean PFS of 32 months compared to 20 months in patients with an RDI of < 70% or > 110% (p = 0.046). 14 patients (10%) had a RDI of < 70%. Conclusions: RDI is a significant predictor of survival in patients with EOC. Effort should be made to achieve an RDI of at least 70%. Dose reductions and treatment delays could be minimized by utilizing prophylactic colony stimulating factors and educating patients about the importance of adhering to their treatment schedule.

AB - Objective: Relative dose intensity (RDI) is the ratio of delivered dose intensity of chemotherapy to standard dose intensity. In this study, we sought to determine the prognostic significance of RDI in patients with epithelial ovarian cancer (EOC). Methods: A retrospective analysis of chemotherapy naïve patients treated between 2001 and 2008 with intravenous taxane and platinum was performed. RDI was calculated as the delivered dose intensity (total dose delivered/total time of therapy) divided by standard dose intensity calculated for each regimen and compared to progression-free survival (PFS). Multivariate recursive partitioning survival analysis was utilized. Results: 138 EOC patients completed initial taxane/platinum-based chemotherapy following surgical cytoreduction. The most common reasons for dose delays and reductions were thrombocytopenia (38%) and neutropenia (31%). 24% of treatment delays were due to social reasons such as transportation constraints or scheduling conflicts. The average RDI was 90% (range, 24-126%). The mean PFS was 31 months (range, 3-117). Patients that achieved an RDI between 70% and 110% had a mean PFS of 32 months compared to 20 months in patients with an RDI of < 70% or > 110% (p = 0.046). 14 patients (10%) had a RDI of < 70%. Conclusions: RDI is a significant predictor of survival in patients with EOC. Effort should be made to achieve an RDI of at least 70%. Dose reductions and treatment delays could be minimized by utilizing prophylactic colony stimulating factors and educating patients about the importance of adhering to their treatment schedule.

UR - http://www.scopus.com/inward/record.url?scp=80051548582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051548582&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.05.023

DO - 10.1016/j.ygyno.2011.05.023

M3 - Article

VL - 122

SP - 532

EP - 535

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -